1-{3-[4-(pyridin-2-yl)piperazin-1-yl]propyl}-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione 2-oxide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-{3-[4-(pyridin-2-yl)piperazin-1-yl]propyl}-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione 2-oxide
• 英文别名: 2-oxido-3-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]benzo[f]benzotriazol-2-ium-4,9-dione
• 化学式: C22H22N6O3
• mdl: MFCD06617104
• 分子量: 418.4
• InChiKey: CNLPWXRRBOOKRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  96.8
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS
  申请人：VM Discovery, Inc.

  公开号：EP2194783B1

  公开（公告）日：2017-07-05
• GAIN-OF-FUNCTION BCL-2 INHIBITORS
  申请人：HOCKENBERY David

  公开号：US20120252839A1

  公开（公告）日：2012-10-04

  Compounds are described that are useful for treating an apoptosis-associated disease, which are specifically cytotoxic to tumor cells that are overexpressing Bcl-x L , and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-x L . Also described is a method for treating an apoptosis-associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active compound that is specifically cytotoxic to tumor cells that are overexpressing Bcl-x L , and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-x L . Several scaffolds of active compounds are described.
• US8865901B2
  申请人：——

  公开号：US8865901B2

  公开（公告）日：2014-10-21
• [EN] METHOD OF INHIBITING BCL-2-RELATED SURVIVAL PROTEINS<br/>[FR] PROCÉDÉ DESTINÉ À INHIBER DES PROTÉINES DE SURVIE APPARENTÉES AUX BCL-2
  申请人：HUTCHINSON FRED CANCER RES

  公开号：WO2011041731A2

  公开（公告）日：2011-04-07

  A method for treating an apoptosis-associated disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an active compound that is specifically cytotoxic to tumor cells that are overexpressing Bcl-xL, and are much less cytotoxic in isogenic cells that are not overexpressing Bcl-xL. Several scaffolds of active compounds are described.
• [EN] GAIN-OF-FUNCTION BCL-2 INHIBITORS<br/>[FR] INHIBITEURS DE BCL-2 À GAIN DE FONCTION
  申请人：HUTCHINSON FRED CANCER RES

  公开号：WO2011041737A2

  公开（公告）日：2011-04-07

  Compounds are described that are useful for treating an apoptosis-associated disease, which are specifically cytotoxic to tumor cells that are overexpressing BcI-XL, and are much less cytotoxic in isogenic cells that are not overexpressing BcI-XL. Methods of using such compounds to treat apoptosis-associated disease is also described.